NAVIDEA BIOPHARMACEUTICALS, INC. (NYSEMKT:NAVB) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
|
Submission of Matters to a Vote of Security Holders. |
At the Special Meeting of Stockholders of Navidea
Biopharmaceuticals, Inc. (the Company) held on March 2, 2017 (the
Special Meeting), the stockholders of the Company voted as set
forth below on the following proposal, which is described in
detail in the Companys definitive proxy statement, filed with the
Securities and Exchange Commission on February 8, 2017. The
stockholders of the Company had also been solicited to vote to
approve an adjournment of the Special Meeting, if necessary, to
solicit additional proxies if there were insufficient votes at
the time of the Special Meeting to approve the Asset Sale
referenced below, but such adjournment was deemed unnecessary.
At the Special Meeting, 98,071,698 shares of common stock, or
approximately 61% of the outstanding common stock entitled to
vote, were represented by proxy or in person.
Proposal 1. Voted to authorize the sale (the Asset Sale) by the
Company of its assets used in connection with its Lymphoseek
business in North America, as defined in and to the Asset
Purchase Agreement, dated as of November 23, 2016, by and between
Navidea Biopharmaceuticals, Inc. and Cardinal Health 414, LLC, as
more fully described in the Proxy Statement.
The following table shows the voting tabulation for the Asset
Sale:
| FOR | AGAINST | ABSTENTIONS | |
| 96,910,957 | 941,736 | 219,005 |
About NAVIDEA BIOPHARMACEUTICALS, INC. (NYSEMKT:NAVB)
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. NAV5001 is an iodine-123 (I-123) radiolabeled single-photon emission computed tomography (SPECT) imaging agent being developed as an aid in the diagnosis of Parkinson’s disease (PD) and other movement disorders, with potential use as a diagnostic aid in dementia. NAV4694 is a fluorine-18 (F-18) radiolabeled positron emission tomography (PET) imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer’s disease (AD) and mild cognitive impairment (MCI). NAVIDEA BIOPHARMACEUTICALS, INC. (NYSEMKT:NAVB) Recent Trading Information
NAVIDEA BIOPHARMACEUTICALS, INC. (NYSEMKT:NAVB) closed its last trading session up +0.182 at 0.670 with shares trading hands.